Gastric Cancer

Things are looking up in the world of adjuvant therapy for patients with gastrointestinal cancers, according to Diane Reidy-Lagunes, MD. During her presentation, Reidy-Lagunes outlined the current state-of-the-art in GI cancer care, with findings from pivotal studies in gastric, pancreatic, biliary, and colorectal cancers.

Maria Svensson, MD, Lund University, discusses the importance of biomarkers in the field of gastric cancers. In a recent study, she used evidence of mismatch repair to determine prognosis of the patients.

According to the results of a study presented during the 2018 ASCO Annual Meeting, microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. 

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of testing for microsatellite instability-high (MSI-H) status in patients with gastric cancers.

Lung Cancer

Lung Cancer

Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced&nbsp;<br /> esophageal or gastric cancer.<br /> &nbsp;